These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37924201)

  • 1. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Hayashi S; Tachibana S; Maeda T; Yamashita M; Shirasugi I; Yamamoto Y; Yamada H; Okano T; Nishimura K; Ueda Y; Jinnno S; Saegusa J; Yamamoto W; Murata K; Fujii T; Hata K; Yoshikawa A; Ebina K; Etani Y; Yoshida N; Amuro H; Hashimoto M; Hara R; Katayama M; Okano T; Kuroda R
    Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37924201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis.
    Hayashi S; Nakano N; Tsubosaka M; Kamenaga T; Kuroda Y; Matsumoto T; Yamada H; Nishimra K; Ueda Y; Saegusa J; Kuroda R
    Clin Rheumatol; 2024 Nov; 43(11):3285-3292. PubMed ID: 39243280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial.
    Liao X; Huo W; Zeng W; Qin F; Dong F; Wei W; Lei L
    Adv Rheumatol; 2023 Oct; 63(1):50. PubMed ID: 37845778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4).
    Tanaka Y; Takeuchi T; Morita Y; Kato D; Kaneko Y; Terada W
    Mod Rheumatol; 2024 Mar; 34(3):453-465. PubMed ID: 37319017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
    Kerschbaumer A; Smolen JS; Nash P; Doerner T; Dougados M; Fleischmann R; Geissler K; McInnes IB; Takeuchi T; Trauner M; Winthrop K; de Wit M; Boehncke WH; Falzon L; van der Heijde D
    RMD Open; 2020 Nov; 6(3):. PubMed ID: 33188136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
    Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Östör A; Ng KJ; Gerwien J; Zaremba-Pechmann L; Brnabic AJM; Fautrel B
    Rheumatol Ther; 2023 Dec; 10(6):1575-1595. PubMed ID: 37755648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
    Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study.
    Kivitz A; Wells AF; Vargas JI; Baraf HSB; Rischmueller M; Klaff J; Khan N; Li Y; Carter K; Friedman A; Durez P
    Rheumatol Ther; 2023 Aug; 10(4):901-915. PubMed ID: 37199884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis.
    Tanaka Y; Okumura H; Kim S; Dorey J; Wojciechowski P; Chorąży J; Kato D; Schultz NM
    Rheumatol Ther; 2021 Jun; 8(2):729-750. PubMed ID: 33725321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis.
    Hernández-Cruz B; Kiltz U; Avouac J; Treuer T; Haladyj E; Gerwien J; Gupta CD; Conti F
    Rheumatol Ther; 2023 Dec; 10(6):1417-1457. PubMed ID: 37715917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.
    Farnos C; Barbier V; Doussiere M; Deprez V; Hamidou Y; Bruy PA; Sobhy Danial JM; Goeb V
    J Clin Med; 2024 Aug; 13(16):. PubMed ID: 39200750
    [No Abstract]   [Full Text] [Related]  

  • 20. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.